PubMed Health⌕ Search

Biomedical subjects

K Kangas

Publications and source records attributed to K Kangas.

3 recordsLinked to original sources
PubMed1978

Non-thrombocytopenic purpuras.

88 cases of microscopical diapedesis of the red blood cells in the superficial blood vessels of the skin were investigated clinically, histologically and immunohistologically. Polymorphonuclear vasculitis (PMNV) was found in 27 cases, 18 of which also demonstrated immunoglobulins (mostly IgM) in the vessel walls. Complement (C3) was found in 16 cases. The cases with PMNV formed a uniform group as regards preceding infections, drug consumption, clinical features, and pathological urinalysis and laboratory data. The second group consisted of 21 cases of lymphocytic perivasculitis with immunoglobulins and/or complement (LP + ig/C3). It clearly differed clinically from the former group in three respects: urinalysis was normal, a slowing of the venous outflow was found in more than half of the cases and the duration of the disease was longer. The biggest group consisted of 40 cases of lymphocytic perivasculitis without detectable immunoglobulins in the vessel walls (LP). In this group the duration of the disease was shortest. The capillary resistance was lower than in the other groups. The results of this investigation indicate that there are at least three pathogenetically differing groups among the clinical purpuric conditions.

Adolescent↗
PubMed1977

Gluten-free diet in dermatitis herpetiformis. I. Clinical response of skin lesions in 81 patients.

Eighty-one patients with dermatitis herpetiformis were treated with a gluten-free diet (GFD) for periods varying from 6 to 36 months. At the end of the treatment the daily requirement of dapsone was significantly lower in patients treated with a GFD than in 49 patients on a normal diet. 93% of the patients on a GFD were able to reduce the dose of dapsone whereas only 16% of the patients on a normal diet were able to do this. Complete remissions occurred only in patients on a GFD. 28% of the patients on a GFD were able to stop dapsone completely and were continuously asymptomatic when they observed a strict diet. A response to a GFD was noted on the mean daily requirement of dapsone as soon as the treatment was initiated although the length of time for an individual response varied. After one year on a GFD the patients needed on average about 40% and after 3 years about 20% of the dose required to control skin symptoms at the beginning of the diet. The patients responded to a GFD irrespective of changes found in the jejunal mucosa and irrespective of the presence of absence of HLA-B8.

Adolescent↗